Aktuellt
SENASTE
Redeye comments on the disappointing news that IRLAB’s drug candidate Pirepemat did not meet its primary endpoint in its phase IIb study targeting PD-fall, which led to a significant sell-off in the share yesterday. We give an initial take but will soon return with an updated valuation where we expect to lower our base case.
LÄS MER
